Valuation: Insulet Corporation

Market Cap 10.31B 9.06B 8.35B 7.8B 14.64B 973B 14.9B 100B 38.78B 480B 38.73B 37.88B 1,667B P/E 2026 *
24.8x
P/E 2027 * 19.3x
Enterprise Value 10.41B 9.15B 8.43B 7.88B 14.78B 983B 15.05B 101B 39.16B 484B 39.1B 38.25B 1,683B EV / Sales 2026 *
3.13x
EV / Sales 2027 * 2.55x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Insulet Corporation

1 day+3.32%
1 week+5.53%
Current month+6.13%
1 month-0.68%
3 months-28.79%
6 months-46.74%
Current year-45.88%
1 week 138.79
Extreme 138.79
154.23
1 month 138.79
Extreme 138.79
161.35
Current year 138.79
Extreme 138.79
299.8
1 year 138.79
Extreme 138.79
354.88
3 years 125.82
Extreme 125.82
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 27.62
Extreme 27.6201
354.88
Manager TitleAgeSince
Chief Executive Officer 55 2025-04-27
Director of Finance/CFO 53 2025-09-29
Compliance Officer 50 2022-11-30
Director TitleAgeSince
Chairman 61 2018-12-31
Director/Board Member 61 2015-07-26
Director/Board Member 59 2017-08-09
Date Insider Type Main position Quantity % Market Cap.
06-02Buy

Director

2,790 0.0040%
06-02Sell

Director

-418 0.0006%
06-02Buy

Director

3,450 0.0049%
Change 5-day change 1-year change 3-year change Capi.($)
+3.32%+5.53%-49.77%-46.56% 10.31B
+3.04%+5.46%-32.14%-13.71% 158B
+0.49%+1.49%-6.34%-7.96% 103B
+0.10%-8.26%+52.40%+56.51% 54.49B
+0.87%+5.56%-1.84%+52.90% 55.35B
+2.44%+5.14%-11.42%-40.99% 40.72B
+4.77%+5.09% - - 30.48B
-1.58%-5.27%-18.93%-45.84% 26.91B
+1.81%+5.67%+56.80%-5.57% 24.05B
+0.27%-2.52%-17.88%-3.19% 19.91B
Average +1.57%+1.61%-3.24%-6.05% 52.24B
Weighted average by Cap. +1.67%+2.38%-6.99%-1.12%

Financials

2026 *2027 *
Net sales 3.32B 2.92B 2.69B 2.51B 4.72B 314B 4.8B 32.27B 12.5B 155B 12.48B 12.21B 537B 3.94B 3.46B 3.19B 2.98B 5.59B 372B 5.69B 38.23B 14.81B 183B 14.79B 14.46B 636B
Net income 432M 380M 350M 327M 613M 40.77B 625M 4.2B 1.63B 20.1B 1.62B 1.59B 69.85B 565M 496M 457M 428M 802M 53.32B 817M 5.49B 2.13B 26.28B 2.12B 2.08B 91.34B
Net Debt 101M 88.42M 81.46M 76.17M 143M 9.5B 145M 977M 379M 4.68B 378M 370M 16.27B -285M -250M -230M -215M -404M -26.87B -412M -2.77B -1.07B -13.25B -1.07B -1.05B -46.03B
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
26-06-25 US$153.82 +3.32% 2,008,254
26-06-24 US$148.88 +3.46% 1,404,142
26-06-23 US$143.90 +3.55% 1,854,938
26-06-22 US$138.97 -4.66% 1,685,321
26-06-18 US$145.76 +1.56% 2,864,144
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
153.82USD
Average target price
240.25USD
Spread / Average Target
+56.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PODD Stock